AVEO - AVEO Pharmaceuticals, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.9200
-0.0400 (-2.04%)
As of 1:05PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close1.9600
Open1.9200
Bid1.92 x 4000
Ask1.93 x 3000
Day's Range1.8900 - 1.9500
52 Week Range1.4000 - 3.5900
Volume389,253
Avg. Volume2,437,607
Market Cap308.413M
Beta (3Y Monthly)2.53
PE Ratio (TTM)N/A
EPS (TTM)-0.20
Earnings DateMay 11, 2017 - May 12, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.50
Trade prices are not sourced from all markets
  • How to spot risky biotech companies and six to avoid now
    MarketWatchyesterday

    How to spot risky biotech companies and six to avoid now

    With biotechnology exchange traded funds down as much as 20% from their highs last year, it’s now tempting to shop for bargains. It had cash of $11 million and annualized losses of $94 million, for a very troubling risk ratio of 0.1.

  • Here's Why These Small-Cap Pharma Stocks Lost as Much as 45% in December
    Motley Fool8 days ago

    Here's Why These Small-Cap Pharma Stocks Lost as Much as 45% in December

    A volatile stock market dished out an extra dose of punishment to riskier assets, including these three small-cap pharma companies.

  • Business Wire16 days ago

    AVEO Oncology to Present at the 37th Annual J.P. Morgan Healthcare Conference

    AVEO Oncology (AVEO) today announced that Michael Bailey, president and chief executive officer, will present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 9, 2019 at 4:00 p.m. Pacific Time. A live webcast of the presentation can be accessed by visiting the investors section of the Company’s website at www.aveooncology.com. AVEO Pharmaceuticals, Inc. (the “Company” or “AVEO”) is a biopharmaceutical company dedicated to advancing a broad portfolio of targeted medicines for oncology and other areas of unmet medical need.

  • Business Wire16 days ago

    AVEO Oncology to Present TIVO-3 Data at the 2019 ASCO Genitourinary Cancers Symposium

    AVEO Oncology (AVEO) today announced that data from the Phase 3 TIVO-3 study of tivozanib (FOTIVDA®) versus sorafenib in refractory advanced or metastatic renal cell carcinoma (RCC) will be presented during an oral session at the 2019 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium being held February 14-16, 2019 in San Francisco. It is a potent, selective and long half-life inhibitor of all three VEGF receptors and is designed to optimize VEGF blockade while minimizing off-target toxicities, potentially resulting in improved efficacy and minimal dose modifications.1,2 Tivozanib has been shown to significantly reduce regulatory T-cell production in preclinical models3, and has demonstrated synergy in combination with nivolumab (anti PD-1) in a Phase 2 study in RCC.

  • ACCESSWIRE23 days ago

    4 Pharma Stocks Heating Up On Wednesday (12/26/18)

    Premier Health Group (PHGRF) (PHGI), ArQule, Inc (ARQL), Amarin Corporation plc (AMRN), and AVEO Pharmaceuticals, Inc (AVEO) are 4 pharma stocks that may be worth keeping tabs on this week. Premier Health Group (PHGRF) (PHGI) is a company determined to improve the quality of care currently made available to consumers in the primary healthcare space. As an industry leader, the Company is focused on developing proprietary technologies to develop healthcare through a network of interconnected primary care clinics by way of artificial intelligence integration and telemedical advancements.

  • Is AVEO Pharmaceuticals, Inc. (AVEO) A Good Stock To Buy?
    Insider Monkey28 days ago

    Is AVEO Pharmaceuticals, Inc. (AVEO) A Good Stock To Buy?

    “Market volatility has picked up again over the past few weeks. Headlines highlight risks regarding interest rates, the Fed, China, house prices, auto sales, trade wars, and more. Uncertainty abounds. But doesn’t it always? I have no view on whether the recent volatility will continue for a while, or whether the market will be back […]

  • Do Options Traders Know Something About AVEO Pharmaceuticals (AVEO) Stock We Don't?
    Zacks29 days ago

    Do Options Traders Know Something About AVEO Pharmaceuticals (AVEO) Stock We Don't?

    Investors need to pay close attention to AVEO Pharmaceuticals (AVEO) stock based on the movements in the options market lately.

  • Zackslast month

    5 Biotech Stocks Set to Bounce Back in '19 After a Rough Ride

    There are some biotech stocks which are down more than 20% this year so far but have the potential to bounce back next year.

  • Business Wirelast month

    AVEO Oncology Announces Immuno-Oncology Clinical Collaboration with AstraZeneca

    AVEO Oncology (AVEO) today announced that it has entered into a clinical collaboration with AstraZeneca to evaluate the safety and efficacy of AstraZeneca's IMFINZI® (durvalumab), a human monoclonal antibody directed against programmed death-ligand 1 (PD-L1), in combination with FOTIVDA® (tivozanib), AVEO’s oral, once-daily, potent and highly-selective vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI) in first-line hepatocellular carcinoma (HCC), or liver cancer, in a Phase 1/2 study. AVEO will serve as the study sponsor, with study costs shared equally by both parties and clinical drug supplied by each respective company. “We are thrilled to collaborate with AstraZeneca to explore another tivozanib-immunotherapy combination and look forward to understanding the potential of combining tivozanib with durvalumab in liver cancer,” said Michael Bailey, president and chief executive officer of AVEO.

  • Why AVEO Pharmaceuticals Stock Tanked Last Month
    Motley Foollast month

    Why AVEO Pharmaceuticals Stock Tanked Last Month

    The company's meager cash position is worrying investors.

  • Business Wirelast month

    AVEO Oncology Announces Extension of Debt Facility Interest Only Period

    AVEO Oncology (AVEO) today announced a six-month extension to the interest only period under its existing amended and restated loan and security agreement with Hercules Capital, Inc. (Hercules). The extension was granted as a result of achieving certain predefined requirements under the agreement, including successfully meeting the primary endpoint of the Company’s Phase 3 TIVO-3 study of tivozanib in refractory advanced or metastatic renal cell carcinoma (RCC), by demonstrating a significant improvement in progression free survival. The Company will begin making principal payments on the $20.0 million facility starting on August 1, 2019.

  • TheStreet.com2 months ago

    2 Small Biotech Stocks That Insiders Are Buying

    The biotech sector continues to see bearish sentiment and trading action. Small biotech stocks rallied just over 2% on Monday to begin a new trading week, but all those gains were given right back in Tuesday's session.

  • GlobeNewswire2 months ago

    New Research Coverage Highlights AVEO Pharmaceuticals, GMS, R1 RCM, Installed Building Products, Stoneridge, and Chicago Rivet & Machine — Consolidated Revenues, Company Growth, and Expectations for 2018

    NEW YORK, Nov. 28, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • Former Aveo CFO misled biotech's investors, jury finds
    American City Business Journals2 months ago

    Former Aveo CFO misled biotech's investors, jury finds

    The SEC accused David Johnston of failing to disclose that the FDA had recommended that Aveo conduct a second late-stage trial of a kidney cancer drug, which was ultimately rejected.

  • Implied Volatility Surging for AVEO Pharmaceuticals (AVEO) Stock Options
    Zacks2 months ago

    Implied Volatility Surging for AVEO Pharmaceuticals (AVEO) Stock Options

    Investors need to pay close attention to AVEO Pharmaceuticals (AVEO) stock based on the movements in the options market lately.

  • ACCESSWIRE2 months ago

    4 Healthcare Stocks You Should Get To Know Before 2019

    New market trends are pushing investors to pay closer attention to the healthcare industry as it has been seen as a safe haven during turbulent times in the broader markets. In fact, according to the "Cognitive Computing and Artificial Intelligence Systems Market in Healthcare" report from ResearchAndMarkets these technologies have gained significant traction. Increased adoption of cognitive and AI platforms can be attributed to their wide application potential across the healthcare industry, including patients and hospitals.

  • Business Wire2 months ago

    AVEO Oncology to Present at the 30th Annual Piper Jaffray Healthcare Conference

    AVEO Oncology (AVEO) today announced that Michael Bailey, president and chief executive officer, will present at the 30th Annual Piper Jaffray Healthcare Conference in New York on Wednesday, November 28, 2018 at 2:30 p.m. Eastern Time. The conference is being held at the Lotte New York Palace Hotel. A live webcast of the presentation can be accessed by visiting the investors section of the Company’s website at www.aveooncology.com.

  • Business Wire2 months ago

    AVEO Oncology Announces $2M Milestone Payment from EUSA Pharma Related to German Commercialization of FOTIVDA®

    AVEO Oncology (AVEO) today announced the triggering of a $2 million milestone payment to AVEO from EUSA Pharma. The milestone payment relates to the commercial launch and reimbursement in Germany of FOTIVDA® (tivozanib) as a first line treatment of adult patients with advanced renal cell carcinoma (RCC). In the European Union, Norway and Iceland, tivozanib is indicated for the first line treatment of adult patients with RCC and for adult patients who are vascular endothelial growth factor receptor (VEGFR) and mTOR pathway inhibitor-naïve following disease progression after one prior treatment with cytokine therapy for RCC.

  • ACCESSWIRE2 months ago

    Drug Sales Up, Biotech Stocks Down, Here's a Profit Opportunity

    HENDERSON, NV / ACCESSWIRE / November 14, 2018 / With the sharp declines in biotechnology stocks, with the iShares Nasdaq Biotechnology exchange traded fund (ETF) and SPDR S&P Biotech ETF recently down ...

  • AVEO Pharmaceuticals (AVEO) Q3 Earnings & Revenues Top Mark
    Zacks2 months ago

    AVEO Pharmaceuticals (AVEO) Q3 Earnings & Revenues Top Mark

    AVEO Pharmaceuticals' (AVEO) loss is narrower than estimated in the third quarter. Also, the company???s revenues beat estimates.

  • AVEO Pharmaceuticals (AVEO) Reports Q3 Loss, Tops Revenue Estimates
    Zacks2 months ago

    AVEO Pharmaceuticals (AVEO) Reports Q3 Loss, Tops Revenue Estimates

    AVEO (AVEO) delivered earnings and revenue surprises of 16.67% and 262.79%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press2 months ago

    AVEO: 3Q Earnings Snapshot

    On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of 18 cents. Losses, adjusted for non-recurring costs, were 5 cents per share. The results beat Wall Street expectations. ...

  • Business Wire2 months ago

    AVEO Reports Third Quarter 2018 Financial Results and Provides Business Update

    AVEO Oncology today reported financial results for the third quarter ended September 30, 2018 and provided a business update.

  • Business Wire2 months ago

    AVEO Oncology Announces Phase 3 TIVO-3 Trial of Tivozanib in Renal Cell Carcinoma Meets Primary Endpoint

    AVEO Oncology (AVEO) today announced positive topline results from the primary analysis of the TIVO-3 trial, the Company’s Phase 3 randomized, controlled, multi-center, open-label study to compare tivozanib (FOTIVDA®) to sorafenib in 351 subjects with highly refractory advanced or metastatic renal cell carcinoma (RCC). The trial met its primary endpoint of demonstrating a statistically significant benefit in progression-free survival (PFS). Among these, approximately 26% of patients received checkpoint inhibitor therapy in earlier lines of treatment.

  • Analysts Estimate AVEO Pharmaceuticals (AVEO) to Report a Decline in Earnings: What to Look Out for
    Zacks3 months ago

    Analysts Estimate AVEO Pharmaceuticals (AVEO) to Report a Decline in Earnings: What to Look Out for

    AVEO (AVEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.